Treatment response of an outpatient training for children with enuresis in a tertiary health care setting

J Pediatr Urol. 2013 Aug;9(4):516-20. doi: 10.1016/j.jpurol.2012.05.010. Epub 2012 Jun 26.

Abstract

Purpose: To evaluate treatment effectiveness for children with enuresis, according to the definitions of the International Children's Continence Society (ICCS, 2006).

Material and methods: Children ≥6 years of age followed a 4-month outpatient treatment consisted of a visit during which history regarding enuresis was taken, causes were explained and therapeutic tips & tricks were discussed. All children received a booklet about enuresis and were trained with an alarm and/or pharmacological therapy. At baseline, 4, 10 and 16 months, the number of wet nights during the previous 28 days and the use of medication were assessed. Success of treatment was determined using ICCS definitions of treatment outcome.

Results: 66 children with enuresis were included (48 boys/18 girls) in this retrospective study. Mean age: 11(± 2.6) years. 91%(n = 60) of the children had non-monosymptomatic enuresis. Results at 4 months: 46% full, 15% good, 21% partial response (n = 66). At 10 months: 55% full, 4% good, 29% partial response (n = 49). At 16 months: 53% full, 6% good, 25% partial response (n = 34). Overall, use of pharmacological therapy showed a decline in time.

Conclusion: According to the ICCS definitions, outpatient treatment for enuresis shows a good overall treatment response, and these results can be used to compare with other studies in the future.

MeSH terms

  • Adolescent
  • Antidiuretic Agents / therapeutic use
  • Child
  • Clinical Alarms
  • Deamino Arginine Vasopressin / therapeutic use*
  • Female
  • Humans
  • Male
  • Nocturnal Enuresis / drug therapy*
  • Nocturnal Enuresis / therapy*
  • Outpatients
  • Pamphlets
  • Patient Education as Topic / methods*
  • Retrospective Studies
  • Tertiary Care Centers*
  • Treatment Outcome
  • Young Adult

Substances

  • Antidiuretic Agents
  • Deamino Arginine Vasopressin